Principal Financial Group Inc Inhibrx, Inc. Call Options Transaction History
Principal Financial Group Inc
- $172 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INBX
# of Institutions
2Shares Held
25.3KCall Options Held
0Put Options Held
0About Inhibrx, Inc.
- Ticker INBX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,057,700
- Market Cap $626M
- Description
- Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...